Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment

Exclusion Criteria

• •Prior systemic anticancer therapy for breast cancer (immunotherapy, hormonotherapy, chemotherapy).
• •Prior anthracycline therapy or taxoids (paclitaxel, docetaxel) for any malignancy.
• •Prior radiation therapy for breast cancer.
• •Bilateral invasive breast cancer.
• •Pregnant, or lactating patients.
• •Patients of childbearing potential must implement adequate non-hormonal contraceptive measures during study treatment .
• •Any T4 or N1-3 or M1 breast cancer.
• •Pre-existing motor or sensory neurotoxicity of a severity grade 2 by NCI criteria.
• •Other serious illness or medical condition
• •Past or current history of neoplasm other than breast carcinoma.
• •Ipsilateral ductal carcinoma in-situ (DCIS) of the breast.
• •Lobular carcinoma in-situ (LCIS) of the breast.
• •Chronic treatment with corticosteroids unless initiated \> 6 months prior to study entry and at low dose
• •Concurrent treatment with ovarian hormonal replacement therapy. Prior treatment should be stopped before study entry.
• •Definite contraindications for the use of corticosteroids.
• •Concurrent treatment with other experimental drugs.
• •Participation in another clinical trial with any investigational not marketed drug within 30 days prior to study entry.
• •Concurrent treatment with any other anti-cancer therapy.
• •Male patients.